Medicare Changed Payment for Diabetic Foot Ulcer Skin Substitutes in 2026. What Patients Should Know

If you have Medicare and are being treated for a diabetic foot ulcer, the main thing to know is this: Medicare changed how it pays for many skin substitute products on January 1, 2026, but a separate set of coverage restrictions that had been scheduled to start at the same time was pulled back before it took effect.

That distinction matters. It means patients should not assume Medicare suddenly stopped covering these products. But clinics may still change which products they keep on hand, how they document wound care, and how they talk with patients about options, costs, and setting of care.

For patients and families, this is more than a billing story. Diabetic foot ulcers can become dangerous quickly if they do not heal. A delayed or worsening wound can lead to infection, hospitalization, or even amputation. So the safest takeaway is simple: Medicare changed payment policy, not the fact that diabetic foot ulcers still need prompt, evidence-based care.

What CMS changed on January 1, 2026

For calendar year 2026, CMS finalized a new payment approach for many skin substitute products used during covered application procedures. In plain language, Medicare moved away from paying most of these products one by one under the older pricing method and instead began treating them more like supplies used as part of the procedure.

The change applies in physician offices and in hospital outpatient departments. CMS also grouped products by their FDA regulatory category and used a single 2026 payment rate framework, with plans to move to more category-specific rates in future years.

CMS said it made the change because Medicare Part B spending on these products rose dramatically in a short period. The agency pointed to spending growth from $252 million in 2019 to more than $10 billion in 2024 and said the new policy was meant to reduce waste and slow spending growth.

That is a payment policy decision, not a blanket medical judgment that every product is ineffective. But it does mean the financial rules around these products changed quickly and in a way clinics had to respond to right away.

What CMS withdrew in late December 2025, and why that matters

Just before the new year, CMS separately announced that Medicare contractors were withdrawing final local coverage determinations for certain skin substitute products used in diabetic foot ulcers and venous leg ulcers. Those local coverage rules had been scheduled to take effect on January 1, 2026, but they were withdrawn on December 24, 2025.

Why does that matter? Because payment and coverage are not the same thing. The payment method changed. The separate final local coverage restrictions did not go into effect.

That is why it would be misleading to say Medicare simply “stopped covering” skin substitutes for diabetic foot ulcers. What happened is more complicated: the payment system changed nationwide, while a more specific coverage tightening was pulled back before it started.

Why diabetic foot ulcers are high-stakes problems

This policy debate matters because diabetic foot ulcers are not minor skin problems. They can be a sign of nerve damage, poor blood flow, infection risk, or all three at once.

CDC says lower-limb amputations are increasing in the United States and that most are related to diabetes complications. High blood sugar over time can damage nerves, making it hard to feel an injury, and can also reduce blood flow, making even a small cut or blister slow to heal. Once infection sets in, the situation can worsen fast.

Patients should not wait on signs of trouble. Pain, numbness, swelling, color change, drainage, a blister or sore that is not healing, or a deep ulcer are reasons to get medical care promptly. If you can see deep tissue or bone, or if there is spreading redness, fever, or worsening pain, that needs urgent medical attention.

Good care for a diabetic foot ulcer usually involves more than one step. Standard treatment often includes taking pressure off the wound, cleaning it and removing dead tissue when needed, treating infection, checking blood flow to the foot and leg, and improving blood sugar control. Skin substitutes, when used, are add-on tools rather than replacements for that basic wound-care work.

What the evidence says about skin substitutes

The evidence here is promising, but it is not simple.

A 2024 scoping review looked at comparative human studies of bioengineered skin substitutes for diabetic foot ulcers. The researchers searched several major databases, identified more than 1,300 articles, and included 24 studies in their final qualitative review. Overall, the studies they included suggested these products often performed better than standard wound care on healing-related outcomes such as wound closure, time to healing, or wound-size reduction.

But that does not mean every product has equally strong evidence behind it. A scoping review is useful for mapping what research exists, but it is not the same as a single large randomized trial or a product-by-product ranking. The studies used different products, different comparisons, and different patient groups. The review also found conflicting evidence when some product types were compared with each other.

So the careful reading is this: skin substitutes may help some diabetic foot ulcers heal, but the evidence base is uneven, and the research does not prove that all products work equally well for all patients in all settings.

How patients may notice the 2026 change in real life

Many patients will never see the billing rules directly, but they may notice the effects around them.

Some clinics may stock fewer products than before or may favor products that fit their new payment and purchasing workflow. Some may spend more time documenting why a product is being used and what standard wound-care steps have already been tried first. In some settings, a product that was previously easy for a clinic to offer may become harder to provide for financial or operational reasons.

That does not automatically mean you will lose access to needed treatment. But it may mean the conversation changes. A wound clinic might recommend a different product than it did in 2025, suggest treatment in a different care setting, or focus more heavily on other wound-care measures before adding a skin substitute.

Hospital outpatient departments and office-based practices may also feel the policy differently because the payment mechanics are not identical in every setting. That is one reason patients may hear more detailed questions about where they are treated and which product is being considered.

Costs are also worth asking about directly. Medicare cost-sharing can vary, and patients should not assume their out-of-pocket costs will stay the same just because the wound treatment plan sounds similar. The practical move is to ask your clinic and your Medicare plan what your share may be before treatment starts, if possible.

Why this is still controversial

The change did not pass quietly. By March 2026, manufacturers were challenging the payment shift in court, and the issue had become part of a broader fight over Medicare spending and wound-care product pricing.

That controversy helps explain why patients may hear mixed messages. But legal and political arguments do not change the immediate medical reality: if you have a nonhealing diabetic foot wound, quick evaluation matters more than the policy debate.

Questions to ask your wound clinic or clinician now

Has your use of skin substitutes changed in 2026?
Is the product you are recommending still offered in this clinic or care setting?
What standard wound-care steps are being used first, such as pressure relief, wound cleaning, infection treatment, blood-flow checks, and blood sugar management?
Why was this specific product chosen for my wound?
What evidence supports it for someone like me?
What is the backup plan if this product is not available, not covered, or not affordable?
What should I watch for at home that means I need help sooner?

What this means for readers: Medicare changed how it pays for many diabetic foot ulcer skin substitutes in 2026, but it did not create a simple “coverage ended” story. Patients may notice changes in clinic workflow and treatment choices, yet the core message is unchanged: do not wait on a worsening foot wound, and make sure the basics of evidence-based wound care are in place whether or not a skin substitute is part of the plan.

Sources

This article is for general informational purposes only and is not medical advice. Research findings can be early, limited, or subject to change as new evidence emerges. For personal guidance, diagnosis, or treatment, consult a licensed clinician. For current outbreak or public health guidance, follow your local health department, the CDC, or another relevant public health authority.